Latest News on Myelofibrosis




Second round of MF Challenge grants to be reviewed (May 2013)

Dr. Ruben Mesa on Late-Stage Trials in Myelofibrosis  (April 2013)

Biotech and Pharmaceutical Companies Helping to Fund Research (February 2013)

Announcing the 2013 MF Challenge (February 2013)


An Expert's Perspective: The Explosive Research in Myelofibrosis (November 2012)  

Winners of MF Challenge Announced (July 2012)

MF Challenge Grant Review takes place in Chicago (June 2012)

Letter from the Chairman on February 29, 2012, Rare Disease Day (February 2012)

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis (February 2012)

New grant opportunity for myelofibrosis (January 2012)

New study on myelofibrosis by Ayalew Tefferi (January 2012)

Update on YM BioSciences MF drug (December 2011)

FDA Approves Incyte's Jakafi(TM) (ruxolitinib) for Patients with Myelofibrosis (November 2011)

SBio to Initiate Global Phase 3 Clinical Trials of its Novel JAK2 Inhibitor Pacritinib for Treatment of Myelofibrosis (October 2011)

YM BioSciences Initiates Phase II BID Trial with CYT387 in Myelofibrosis (September 2011)

How one doctor treats myelofibrosis (April 2011)

SBio reports positive data on JAK2 Inhibitor trial for MF patients (December 2010)

Study tests new prognostic tool for myelofibrosis (March 2010)

Major grant awarded for leukemia and myelofibrosis (February 2010)

Survival study on Myelofibrosis patients published by Dr. Tefferi (PDF)

Discovery of a new mutation in JAK2V617F negative myelofibrosis patients


Make a Donation
to support the MF Challenge
Donate Now!
Learn More About
MF Research
Resource Center


LLS Logo MPN Logo